In a merger between two subcutaneous drug delivery companies, Halozyme Therapeutics is paying $750 million in cash to acquire Elektrofi. Aside from the $750 million upfront payment, the deal also ...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most undervalued biotech stocks to buy right now. Halozyme ...
Earlier this week, Halozyme Therapeutics’ subsidiary Halozyme Hypercon announced a global exclusive collaboration and license agreement granting Vertex Pharmaceuticals access to its Hypercon ...
U.S. company Halozyme Therapeutics, regarded as a competitor to Korea's bio corporations Alteogen, will acquire Elektrofi, which has subcutaneous injection drug delivery technology, for up to $900 ...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most undervalued biotech stocks to buy right now. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on April 7 that its wholly-owned ...
Halozyme has previously licensed the Hypercon technology to other pharmaceutical companies including Janssen, Eli Lilly, and argenx. The company is also known for its ENHANZE drug delivery technology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results